Videos

In this final part of a two-part video series, Senior Editor Peter Wehrwein spoke with Vayong Moua, the Director of Racial and Health Equity Advocacy for Blue Cross and Blue Shield of Minnesota (BCBSMN), about healthcare equity issues, how they relate to access issues, the political determinants of health and killing of George Floyd.

In this first part of a two-part video series, Senior Editor Peter Wehrwein spoke with Vayong Moua, the Director of Racial and Health Equity Advocacy for Blue Cross and Blue Shield of Minnesota (BCBSMN), about healthcare equity issues, how they relate to access issues, the political determinants of health and killing of George Floyd.

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Thomas P. Leist, MD, PhD, says one of the things secondary progressive multiple sclerosis professionals struggle with is making the most effective treatment available to patients, very early on, most likely due to financial reasons.

In this second part of a two-part video series, MHE Senior Editor Peter Wehrwein and Associate Editor Briana Contreras speak with Perry Cohen, Pharm. D., CEO of The Pharmacy Group. Perry has been on MHE's Editorial Advisory Board for over 25 years and has contributed a number of interviews and guest articles toward the publication. In this discussion, Briana, Peter and Perry talked about Sweden, Japan and the United States' response to COVID-19 and Cohen addresses the U.S.'s response under the new President Joe Biden Administration.

In this first of a two-part video series, MHE Senior Editor Peter Wehrwein and Associate Editor Briana Contreras speak with Perry Cohen, Pharm. D., CEO of The Pharmacy Group. Perry has been on MHE's Editorial Advisory Board for over 25 years and has contributed a number of interviews and guest articles toward the publication. In this discussion, Briana, Peter and Perry talked about the current pharmacy benefits market as well as Sweden, Japan and the United States' response to COVID-19.

A partnership between the Morehouse School of Medicine and CommonSpirit Health aims to create more diversity in the medical field.

Two experts discuss the importance of diversity when educating and training healthcare workers.

A remote monitoring system detects indicators of worsening heart failure.

Philip Adamson, M.D., M.Sc., details the relationship between cardiovascular manifestations and COVID-19.

Sumit Dutta, MD, MBA, of OptumRx, talks to MHE about drug use among Americans during the COVID-19 pandemic and about vaccine distribution to its members in this part two of a two-part video interview series.

There currently aren't enough vaccines in the United States, and between the Pfizer and Moderna vaccines, the two are very important to get their hands on, Sumit Dutta, MD, MBA, of OptumRx, says in this part one of a two-part video interview series.

Considerations regarding the impact of COVID-19 on managing patients with behavior-driven conditions, and its positive effects on increasing attention around the topic of prescription digital therapeutics.

Healthcare providers comment on what clinicians would like to see, in terms of data and education, that would help justify the prescribing of digital therapeutics for behavior-driven conditions.

Steven Peskin, MD, MBA, FACP, shares perspective on factors that need to be considered by payers when making decisions about how to cover and reimburse for prescription digital therapeutics used to manage behavior-driven conditions.

Current experiences noted by various stakeholders in healthcare regarding the impact of prescription digital therapeutics in clinical practice as tools to help manage patients with behavior-driven conditions, and current limitations that need to be addressed to increase their uptake.

Considerations regarding opportunities to increase payer and provider uptake of prescription digital therapeutics into clinical practice to optimize care for patients with behavior-driven conditions.

Payer and provider insight regarding the potential impact prescription digital therapeutics could have on addressing challenges surrounding the management of behavior-driven conditions.

Nidal Moukaddam, MD, PhD, Baylor College of Medicine, comments on where she sees prescription digital therapeutics being most useful when managing behavior-driven conditions.

Clinicians, a pharmacist, and a payer discuss their current experience with prescription digital therapeutics for behavior-driven conditions and share considerations for expanding on their use in clinical practice.